Esperion Therapeutics Inc. announced the nomination of ESP-2001, a highly-specific allosteric ATP citrate lyase (ACLY) inhibitor, as a preclinical development candidate for the treatment of primary sclerosing cholangitis $(PSC)$. The company highlighted promising preclinical data showing that ESP-2001 consistently reduced markers of liver and bile duct injury, inflammation, and fibrosis in multiple models. The results have not yet been presented, as Esperion plans to begin Investigational New Drug (IND)-enabling studies and aims to submit an IND to the FDA to initiate first-in-human clinical trials in 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Esperion Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9545384-en) on October 16, 2025, and is solely responsible for the information contained therein.